GetTopicDetailResponse(id=34b515624f9, topicName=ROR1, introduction=ROR1, content=null, image=null, comments=1, allHits=1790, url=https://h5.medsci.cn/topic?id=15624, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=2229, tagList=[TagDto(tagId=2229, tagName=ROR1)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2247026, encodeId=5d7d224e02604, content=<a href='/topic/show?id=34b515624f9' target=_blank style='color:#2F92EE;'>#ROR1#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗體偶聯(lián)藥物#</a>, objectTitle=ROR1靶向ADC的研究進展, objectType=article, longId=783646, objectId=fcfde83646f5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=fcfde83646f5, replyNumber=0, likeNumber=38, createdTime=2025-01-08, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=fcfde83646f5, moduleTitle=ROR1靶向ADC的研究進展, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fcfde83646f5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2242318, encodeId=730b22423189e, content=<a href='/topic/show?id=34b515624f9' target=_blank style='color:#2F92EE;'>#ROR1#</a> <a href='/topic/show?id=567650039e9' target=_blank style='color:#2F92EE;'>#彌漫大B細胞淋巴瘤#</a> <a href='/topic/show?id=f7561223162e' target=_blank style='color:#2F92EE;'>#Zilovertamab vedotin#</a>, objectTitle=100%CR! 驚為天人! ROR1靶點的ADC——zilovertamab vedotin治療彌漫大B細胞淋巴瘤, objectType=article, longId=855293, objectId=6225855293a9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241101/789d870b61c9429bb2ffc79cd9da6a61-wwW9lkL6XFqp.jpg, objectUrl=/article/show_article.do?id=6225855293a9, replyNumber=0, likeNumber=52, createdTime=2024-12-14, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=6225855293a9, moduleTitle=100%CR! 驚為天人! ROR1靶點的ADC——zilovertamab vedotin治療彌漫大B細胞淋巴瘤, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6225855293a9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=896233, encodeId=374789623380, content=<a href='/topic/show?id=34b515624f9' target=_blank style='color:#2F92EE;'>#ROR1#</a>為<a href='/topic/show?id=07a69996557' target=_blank style='color:#2F92EE;'>#靶點#</a>, 新靶點都是有潛力的！, objectTitle=基石藥業(yè)引進靶向ROR1的抗體偶聯(lián)藥物LCB71，超3.6億美元！, objectType=article, longId=202793, objectId=71ca202e93e4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201009/fb30d751a22647eba5a43a85474d6c9a.jpg, objectUrl=/article/show_article.do?id=71ca202e93e4, replyNumber=0, likeNumber=0, createdTime=2020-11-02, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71ca202e93e4, moduleTitle=基石藥業(yè)引進靶向ROR1的抗體偶聯(lián)藥物LCB71，超3.6億美元！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=71ca202e93e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
